SUPERNUS PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent, Diluted
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Net Income (Loss) Attributable to Parent, Diluted of $113.06 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2020-02-28
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2018-12-31 was $25.89M, a 89.58% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2018-09-30 was $28.01M, a 77.68% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2018-06-30 was $30.74M, a 78.21% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2018-03-31 was $26.35M, a 160.55% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2019 was $113.06M, a 1.86% increase from fiscal 2018.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2018 was $110.99M, a 93.65% increase from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2017 was $57.32M, a 36.88% decline from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. net income (loss) attributable to parent, diluted for fiscal 2016 was $90.81M, a 529.37% increase from fiscal 2015.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 3 month as first filed | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 6 month as first filed | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 9 month as first filed | Net Income (Loss) Attributable to Parent, Diluted 12 month | Net Income (Loss) Attributable to Parent, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $113.06M 10-K · filed 2020-02-28 | |||||||
| 2018-12-31 | $25.89M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $53.90M derived: sum of 2 quarters · filed 2020-02-28 | $84.64M derived: sum of 3 quarters · filed 2020-02-28 | $110.99M 10-K · filed 2020-02-28 | ||||
| 2018-09-30 | $28.01M 10-Q · filed 2018-11-09 | $58.75M derived: sum of 2 quarters · filed 2018-11-09 | $85.10M 10-Q · filed 2018-11-09 | $98.76M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $30.74M 10-Q · filed 2018-08-09 | $57.09M 10-Q · filed 2018-08-09 | $70.75M derived: sum of 3 quarters · filed 2020-02-28 | $86.51M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $26.35M 10-Q · filed 2018-05-10 | $40.01M derived: sum of 2 quarters · filed 2020-02-28 | $55.77M derived: sum of 3 quarters · filed 2020-02-28 | $73.02M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2017-12-31 | $13.66M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $29.42M derived: sum of 2 quarters · filed 2020-02-28 | $46.67M derived: sum of 3 quarters · filed 2020-02-28 | $57.32M 10-K · filed 2020-02-28 | ||||
| 2017-09-30 | $15.77M 10-Q · filed 2018-11-09 | $33.01M derived: sum of 2 quarters · filed 2018-11-09 | $43.66M 10-Q · filed 2018-11-09 | $57.60M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $17.25M 10-Q · filed 2018-08-09 | $27.62M 10-Q · filed 2018-08-09 | $41.84M derived: sum of 3 quarters · filed 2019-03-01 | $103.04M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $10.11M 10-Q · filed 2018-05-10 | $24.59M derived: sum of 2 quarters · filed 2019-03-01 | $85.79M derived: sum of 3 quarters · filed 2019-03-01 | $95.26M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $14.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $75.67M derived: sum of 2 quarters · filed 2019-03-01 | $85.15M derived: sum of 3 quarters · filed 2019-03-01 | $90.81M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $61.20M 10-Q · filed 2017-11-09 | $70.67M derived: sum of 2 quarters · filed 2017-11-09 | $76.33M 10-Q · filed 2017-11-09 | $81.62M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $9.47M 10-Q · filed 2017-08-03 | $9.24M 10-Q · filed 2016-08-05 | $14.43M 10-Q · filed 2017-08-03 | $14.36M 10-Q · filed 2016-08-05 | $20.42M derived: sum of 3 quarters · filed 2018-03-01 | $24.48M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-03-31 | $4.06M 10-Q · filed 2017-05-09 | $4.22M 10-Q · filed 2016-05-10 | $10.94M derived: sum of 2 quarters · filed 2018-03-01 | $15.01M derived: sum of 3 quarters · filed 2018-03-01 | $17.27M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $6.89M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $10.95M derived: sum of 2 quarters · filed 2018-03-01 | $13.21M derived: sum of 3 quarters · filed 2018-03-01 | $14.43M 10-K · filed 2018-03-01 | $14.50M 10-K · filed 2016-03-09 | |||
| 2015-09-30 | $4.07M 10-Q/A · filed 2017-01-20 | $4.37M 10-Q · filed 2015-11-09 | $6.33M derived: sum of 2 quarters · filed 2017-01-23 | $7.54M 10-Q/A · filed 2017-01-20 | $7.59M 10-Q · filed 2015-11-09 | $10.85M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-06-30 | $2.26M 10-Q/A · filed 2017-01-23 | $1.83M 10-Q · filed 2015-08-07 | $3.18M 10-Q/A · filed 2017-01-23 | $2.92M 10-Q · filed 2015-08-07 | $6.79M derived: sum of 3 quarters · filed 2017-03-16 | $4.42M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-03-31 | $738.00K 10-Q/A · filed 2017-01-20 | $917.00K 10-Q · filed 2016-05-10 | $4.53M derived: sum of 2 quarters · filed 2017-03-16 | $2.15M derived: sum of 3 quarters · filed 2017-03-16 | $5.36M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $3.79M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $1.42M derived: sum of 2 quarters · filed 2017-03-16 | $4.62M derived: sum of 3 quarters · filed 2017-03-16 | -$10.93M 10-K · filed 2017-03-16 | $16.30M 10-K · filed 2015-03-12 | |||
| 2014-09-30 | -$2.37M 10-Q/A · filed 2017-01-20 | $19.89M 10-Q · filed 2014-11-12 | $831.00K derived: sum of 2 quarters · filed 2017-01-20 | -$14.71M 10-Q/A · filed 2017-01-20 | $6.68M 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | $3.20M 10-Q · filed 2015-08-07 | -$12.34M 10-Q · filed 2015-08-07 | ||||||
| 2013-12-31 | -$92.27M 10-K/A · filed 2017-01-20 | |||||||
| 2012-12-31 | -$47.43M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |